Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Pulmoner Arteriyel Hipertansiyona Bağlı Gelişen Epitel ve Endotel Hasarının Belirlenmesinde Kullanılan Biyobelirteçler: Geleneksel Derleme
Use of Biomarkers for Detecting of Epithelial and Endothelial Damage Due to Pulmonary Arterial Hypertension: Traditional Review
Nimet İSMAİLOĞLUa, Mahmut OKa, Mutlu SEVİNÇa
aKonya Selçuk Üniversitesi Veteriner Fakültesi, İç Hastalıkları ABD, Konya, TÜRKİYE
Turkiye Klinikleri J Vet Sci. 2021;12(2):92-101
doi: 10.5336/vetsci.2020-78244
Article Language: TR
Full Text
ÖZET
 Pulmoner arteriyel hipertansiyon (PAH), ortalama pulmoner arter basıncında ve pulmoner vasküler dirençte artışla karakterize bir hastalıktır. PAH'ın etiyolojisi tam olarak anlaşılamamış olsa da altında birçok neden yattığı bildirilmektedir. Etiyolojisinde birçok etmenin rol oynadığı PAH'da, semptomlar çoğunlukla spesifik değildir. PAH'ın, birçok doku ve organda hasara neden olduğu bildirilmiştir. Son yıllarda PAH'ın solunum ve dolaşım sistemi üzerindeki etkilerinden dolayı üzerinde durulan bir hastalık hâline gelmesine neden olmuştur. PAH'ın teşhisinde invaziv yöntemlerin kullanılıyor olması, hastalığın takibini zorlaştırmaktadır. Noninvaziv yöntem olarak doku ve organlardaki hasarların erken belirlenmesini sağlayan biyobelirteçler kullanılmaya başlanmıştır. Biyobelirteçler yardımıyla hastalığın daha kolay izlenmesi, teşhis ve tedaviye daha çabuk ulaşılması hedeflenilmiştir. Son yıllarda hastalıkların teşhis ve takibinde, doku ve organlara özgü biyobelirteçler ön plana çıkmıştır. Bu derlemede, PAH'a bağlı gelişen kardiyopulmoner endotel ve epitel hasarın erken belirlenmesinde, noninvaziv tanı yöntem olarak oldukça faydalı olduğu kabul edilen biyobelirteçler hakkında yeni ve detaylı bilgi sunulmuştur.

Anahtar Kelimeler: Pulmoner arteriyel hipertansiyon; tanı yöntemi; endotel ve epitel hasar biyobelirteçleri
ABSTRACT
 Pulmonary arterial hypertension (PAH) is a disease characterized by an increase in mean pulmonary arterial pressure and pulmonary vascular resistance. Although the etiology of PAH is not fully understood, it is reported that many reasons under it. Where many factors play a role in etiology of PAH, the symptoms are mostly nonspecific. PAH has been reported to cause damage to many tissues and organs. In recent years, PAH has become a disease that is emphasized due to its effects on the respiratory and circulatory system. The use of invasive methods in the diagnosis of PAH makes the follow-up of the disease difficult. Biomarkers that enable early detection of damage to tissues and organs have begun to be used as a noninvasive method. With the help of biomarkers, it is aimed to monitor the disease more easily, to reach diagnosis and treatment faster. In recent years, tissue and organspecific biomarkers have come to the fore in the diagnosis and followup of diseases. In this review, new and detailed information about biomarkers, which are considered to be very useful as a noninvasive diagnostic method in the early determination of cardiopulmonary endothelium and epithelial damage due to PAH is presented.

Keywords: Pulmonary arterial hypertension; diagnostic method; endothelium and epithelial damage biomarkers
REFERENCES:
  1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1): 1801913. [Crossref]  [PubMed]  [PMC] 
  2. Hewes JL, Lee JY, Fagan KA, Bauer NN. The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers. Pulm Circ. 2020;10(1):2045894019892801. [Crossref]  [PubMed]  [PMC] 
  3. Stewart DJ. Bone morphogenetic protein receptor-2 and pulmonary arterial hypertension: unraveling a riddle inside an enigma? Circ Res. 2005;96:1033-5. [Crossref]  [PubMed] 
  4. Bonagura JD, O'Grady MR, Herring DS. Echocardiography. Principles of interpretation. Vet Clin North Am Small Anim Pract. 1985;15(6):1177-94. [Crossref]  [PubMed] 
  5. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609-16. [Crossref]  [PubMed] 
  6. Bergemann R, Allsopp J, Jenner H, Daniels FA, Drage E, Samyshkin Y, et al; SPHInX Project team. High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project. Pulm Circ. 2018;8(4): 2045894018798613. [Crossref]  [PubMed]  [PMC] 
  7. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med. 1999;13(5):440-7. [Crossref]  [PubMed] 
  8. Visser LC, Wood JE, Johnson LR. Survival characteristics and prognostic importance of echocardiographic measurements of right heart size and function in dogs with pulmonary hypertension. J Vet Intern Med. 2020;34(4): 1379-88. [Crossref]  [PubMed]  [PMC] 
  9. Pyle RL, Abbott J, MacLean H. Pulmonary hypertension and cardiovascular sequelae in 54 dogs. Intern J Appl Res Vet Med. 2004;2(2):99-109. [Link] 
  10. Stepien RL. Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs. J Small Anim Pract. 2009;50 Suppl 1:34-43. [Crossref]  [PubMed] 
  11. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-9. [Crossref]  [PubMed] 
  12. Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A, et al. Vascular smooth muscle contraction in hypertension. Cardiovasc Res. 2018;114(4): 529-39. [Crossref]  [PubMed]  [PMC] 
  13. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. [Crossref]  [PubMed]  [PMC] 
  14. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005;258(3):199-215. [Crossref]  [PubMed] 
  15. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131(3):657-63. [Crossref]  [PubMed] 
  16. Blondonnet R, Constantin JM, Sapin V, Jabaudon M. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers. 2016;2016:3501373. [Crossref]  [PubMed]  [PMC] 
  17. Foris V, Kovacs G, Tscherner M, Olschewski A, Olschewski H. Biomarkers in pulmonary hypertension: what do we know? Chest. 2013;144(1):274-83. [Crossref]  [PubMed] 
  18. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008;32(2):503-12. [Crossref]  [PubMed] 
  19. Anwar A, Ruffenach G, Mahajan A, Eghbali M, Umar S. Novel biomarkers for pulmonary arterial hypertension. Respir Res. 2016;17(1): 88. [Crossref]  [PubMed]  [PMC] 
  20. Hoendermis ES. Pulmonary arterial hypertension: an update. Neth Heart J. 2011;19(12):514-22. [Crossref]  [PubMed]  [PMC] 
  21. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-23. [Crossref]  [PubMed] 
  22. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al; American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 Suppl): 14S-34S. [Crossref]  [PubMed] 
  23. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2007;3(7):737-47. [Crossref]  [PubMed]  [PMC] 
  24. Santos JG, Carmona S, Sequeira JA, Prata A, Santos AI. Pulmonary ventilation/perfusion single photon emission tomography--Initial experience of a Nuclear Medicine Department. Rev Port Pneumol (2006). 2016;22(1):27-33. [Crossref]  [PubMed] 
  25. Woodhead F, Wells AU, Desai SR. Pulmonary complications of connective tissue diseases. Clin Chest Med. 2008;29(1):149-64, vii. [Crossref]  [PubMed] 
  26. Vagvala SH, O'Connor SD. Imaging of abnormal liver function tests. Clin Liver Dis (Hoboken). 2018;11(5):128-34. [Crossref]  [PubMed]  [PMC] 
  27. Şahan C, Cengiz K. Primer antifosfolipid sendromu [Primary anti-phospholipid syndrome]. OMÜ Tıp Dergisi. 2005;22(2):100-11.
  28. Teran F. Resuscitative cardiopulmonary ultrasound and transesophageal echocardiography in the emergency department. Emerg Med Clin North Am. 2019;37(3):409-30. [Crossref]  [PubMed] 
  29. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24(19):1710-8. [Crossref]  [PubMed] 
  30. Seino Y, Ogata K, Takano T, Ishii J, Hishida H, Morita H, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med. 2003;115(3):185-90. [Crossref]  [PubMed] 
  31. Yardan T, Demircan S, Aygün D, Doğanay Z. B-Tipi Natriüretik Peptidin Kalp Yetersizliğindeki Yeri. J Exp Clin Med. 2009; 21(4):188-94.
  32. Köse Sİ, Maden M. Biyomarkerlar ve klinik kullanımları [Biomarkers and their clinical uses]. Dicle Üniv Vet Fak Derg. 2013;2(1):1-8. [Link] 
  33. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463-6. [Crossref]  [PubMed]  [PMC] 
  34. Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173(9):1008-15. [Crossref]  [PubMed]  [PMC] 
  35. Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S, et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation. 2009;119(3):374-81. [Crossref]  [PubMed] 
  36. Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, Makita K, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells. 2004;9(2):165-74. [Crossref]  [PubMed] 
  37. Jabaudon M, Blondonnet R, Roszyk L, Pereira B, Guérin R, Perbet S, et al. Soluble forms and ligands of the receptor for advanced glycation end-products in patients with acute respiratory distress syndrome: an observational prospective study. PLoS One. 2015;10(8): e0135857. [Crossref]  [PubMed]  [PMC] 
  38. Johnson MD, Widdicombe JH, Allen L, Barbry P, Dobbs LG. Alveolar epithelial type I cells contain transport proteins and transport sodium, supporting an active role for type I cells in regulation of lung liquid homeostasis. Proc Natl Acad Sci U S A. 2002;99(4):1966-71. [Crossref]  [PubMed]  [PMC] 
  39. Dobbs LG, Gonzalez R, Matthay MA, Carter EP, Allen L, Verkman AS. Highly water-permeable type I alveolar epithelial cells confer high water permeability between the airspace and vasculature in rat lung. Proc Natl Acad Sci U S A. 1998;95(6):2991-6. [Crossref]  [PubMed]  [PMC] 
  40. Newman V, Gonzalez RF, Matthay MA, Dobbs LG. A novel alveolar type I cell-specific biochemical marker of human acute lung injury. Am J Respir Crit Care Med. 2000;161(3 Pt 1):990-5. [Crossref]  [PubMed] 
  41. Frerking I, Günther A, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med. 2001;27(11):1699-717. [Crossref]  [PubMed] 
  42. Cheng IW, Ware LB, Greene KE, Nuckton TJ, Eisner MD, Matthay MA. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med. 2003;31(1):20-7. [Crossref]  [PubMed] 
  43. Ishizaka A, Matsuda T, Albertine KH, Koh H, Tasaka S, Hasegawa N, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2004;286(6):L1088-94. [Crossref]  [PubMed] 
  44. Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy. 2000;30(4):469-75. [Crossref]  [PubMed] 
  45. Veyradier A, Nishikubo T, Humbert M, Wolf M, Sitbon O, Simonneau G, et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation. 2000; 102(20):2460-2. [Crossref]  [PubMed] 
  46. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122(12):4306-13. [Crossref]  [PubMed]  [PMC] 
  47. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-8. [Crossref]  [PubMed] 
  48. Voelkel NF, Gomez-Arroyo J. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol. 2014;51(4):474-84. [Crossref]  [PubMed] 
  49. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol. 2000;22(6):657-64. [Crossref]  [PubMed] 
  50. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106-14. [Crossref]  [PubMed] 
  51. Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Maître B, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1493-9. [Crossref]  [PubMed] 
  52. Lassus P, Turanlahti M, Heikkilä P, Andersson LC, Nupponen I, Sarnesto A, et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1981-7. [Crossref]  [PubMed] 
  53. Partovian C, Adnot S, Raffestin B, Louzier V, Levame M, Mavier IM, et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol. 2000;23(6):762-71. [Crossref]  [PubMed] 
  54. Azamfirei L, Gurzu S, Solomon R, Copotoiu R, Copotoiu S, Jung I, et al. Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome. Minerva Anestesiol. 2010;76(8):609-16. [Crossref]  [PubMed] 
  55. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res. 2013;319(9):1271-80. [Crossref]  [PubMed] 
  56. Binnie A, Tsang JL, dos Santos CC. Biomarkers in acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20(1): 47-55. [Crossref]  [PubMed] 
  57. Tsigkos S, Koutsilieris M, Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs. 2003;12(6):933-41. [Crossref]  [PubMed] 
  58. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12(2):235-9. [Crossref]  [PubMed] 
  59. Bhandari V, Elias JA. The role of angiopoietin 2 in hyperoxia-induced acute lung injury. Cell Cycle. 2007;6(9):1049-52. [Crossref]  [PubMed] 
  60. Wada T, Jesmin S, Gando S, Yanagida Y, Mizugaki A, Sultana SN, et al. The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) associated with critical illness. J Inflamm (Lond). 2013;10(1):6. [Crossref]  [PubMed]  [PMC] 
  61. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol. 1986;137(1):245-54. [PubMed] 
  62. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol. 1999;66(6): 876-88. [Crossref]  [PubMed] 
  63. Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13(6):R174. [Crossref]  [PubMed]  [PMC] 
  64. Gando S, Kameue T, Matsuda N, Hayakawa M, Ishitani T, Morimoto Y, et al. Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. Thromb Haemost. 2002;88(6):943-9. [Crossref]  [PubMed] 
  65. Burnham EL, Moss M, Harris F, Brown LA. Elevated plasma and lung endothelial selectin levels in patients with acute respiratory distress syndrome and a history of chronic alcohol abuse. Crit Care Med. 2004;32(3):675-9. [Crossref]  [PubMed] 
  66. Osaka D, Shibata Y, Kanouchi K, Nishiwaki M, Kimura T, Kishi H, et al. Soluble endothelial selectin in acute lung injury complicated by severe pneumonia. Int J Med Sci. 2011;8(4):302-8. [Crossref]  [PubMed]  [PMC] 
  67. Johnson LR, Stern JA. Clinical features and outcome in 25 dogs with respiratory-associated pulmonary hypertension treated with sildenafil. J Vet Intern Med. 2020;34(1):65-73. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com